# Postpartum Hemorrhage

Postpartum hemorrhage requires objective blood-loss measurement, immediate treatment linked to predefined triggers, rapid evaluation of tone, trauma, tissue, and thrombin, and early escalation when first-response measures fail. Current evidence supports a coordinated bundle rather than sequential, delayed intervention.

**Clinical question:** How should clinicians detect, treat, and escalate care for postpartum hemorrhage to prevent severe maternal morbidity and death?

Updated: 2026-08-20T23:41:35.331552Z

## What matters in practice
- Use objective postpartum blood-loss measurement rather than visual estimation; visual estimation detects only about 48% of PPH at the 500-mL threshold in pooled data. [24]
- Initiate first-response treatment at measured blood loss of at least 500 mL, or at least 300 mL plus tachycardia, hypotension, or shock index greater than 1. [16]
- For diagnosed PPH, implement uterine massage, an oxytocic, IV tranexamic acid, isotonic crystalloid, genital-tract examination, and escalation concurrently; ideally begin all available bundle elements within 15 minutes. [16]
- Give IV tranexamic acid as soon as possible and within 3 hours of birth; the recommended regimen is 1 g IV over 10 minutes, repeated once if bleeding persists after 30 minutes or recurs within 24 hours. [16]
- Persistent hemorrhage after first-response care requires prompt cause-directed intervention and escalation to tamponade, embolization when available, operative hemostasis, or hysterectomy; do not allow temporizing measures to delay definitive care. [16]

## Recognize PPH early with quantitative blood loss and physiologic assessment

Detection should trigger treatment, not merely document a volume.

The conventional definition of maternal hemorrhage used in ACOG Practice Bulletin No. 183 is cumulative blood loss of at least 1,000 mL or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours after birth. [4] The 2025 WHO/FIGO/ICM guidance instead provides a therapeutic threshold for initiating first-response treatment: objectively measured blood loss of at least 500 mL, or at least 300 mL with any abnormal hemodynamic sign—pulse greater than 100 beats/min, systolic blood pressure below 100 mmHg, diastolic blood pressure below 60 mmHg, or shock index greater than 1—whichever occurs first. Continue heightened surveillance through the first 2 hours and clinical monitoring through 24 hours. [16]

Visual estimation is an inadequate sole detection method. In a diagnostic review of vaginal births, visual estimation versus gravimetric measurement had pooled sensitivity of 48% and specificity of 97% for blood loss of at least 500 mL. A calibrated drape plus clinical observations had sensitivity of 93% and specificity of 95%. [24] Implement objective quantification in every birth, with an explicit response pathway available at the bedside. [16]
- Assess uterine tone immediately after placental delivery and frequently during the first postpartum hour; a boggy uterus should prompt an immediate clinical response. [16]
- Treat the threshold as a trigger for first-response care and referral decisions, not as a requirement to wait before acting on clinically obvious brisk bleeding or instability. [16]
- For cesarean birth, intraoperative quantitative blood-loss assessment and vital-sign interpretation are more complex, but the physiologic consequences of a given blood-loss volume are not expected to differ by delivery route. [16]

*Therapeutic criteria for initiating first-response PPH treatment. [16]*

| Finding | Action |
| --- | --- |
| Objectively measured blood loss at least 500 mL within 24 hours | Diagnose PPH for first-response treatment purposes and activate the response bundle. [16] |
| Blood loss at least 300 mL plus pulse greater than 100/min, systolic BP below 100 mmHg, diastolic BP below 60 mmHg, or shock index greater than 1 | Initiate first-response treatment without waiting for 500 mL blood loss. [16] |
| Heavy ongoing bleeding, suspected concealed hemorrhage, or clinical deterioration | Escalate based on clinical judgment regardless of measured volume. [16] |

## Prevent atony and prepare for hemorrhage before delivery

Universal prophylaxis and system readiness are more reliable than risk-factor screening alone.

A quality-assured uterotonic is recommended during the third stage of labor for all births. Oxytocin 10 IU IM or IV is the preferred prophylactic agent when multiple options are available. [16] For vaginal birth with existing IV access, 10 IU diluted and administered slowly over 1 to 2 minutes is preferred to IM administration; IV access should not be placed solely to administer prophylactic oxytocin. [16]

Heat-stable carbetocin 100 mcg IM or IV is an option where oxytocin cold-chain integrity cannot be assured. Oral misoprostol 400 or 600 mcg is an alternative when injectable uterotonics cannot be administered, including settings without skilled personnel; shivering, fever, and diarrhea are more frequent than with oxytocin. [16] Ergometrine/methylergometrine, fixed oxytocin-ergometrine combinations, and injectable prostaglandins are not recommended for routine PPH prevention because safer alternatives are available and adverse effects, particularly hypertension with ergot-containing products, are important. [16]

Routine prophylactic tranexamic acid is not recommended for either vaginal or cesarean birth in the WHO guideline because evidence does not show added benefit beyond standard prophylaxis and a small thromboembolic risk cannot be excluded. This prevention recommendation does not apply to TXA treatment of established PPH. [16]
- Maintain a hemorrhage protocol, blood-loss measurement supplies, uterotonics, TXA, IV-fluid supplies, and an organized hemorrhage cart or equivalent point-of-care kit. [16]
- Use simulation-based multidisciplinary PPH training and audit adherence to prophylactic uterotonic use, objective blood-loss measurement, and timely bundle delivery. [16]
- Optimize antenatal anemia management; IV iron is recommended over oral iron when oral therapy is not tolerated or rapid correction of confirmed iron-deficiency anemia is clinically necessary and anaphylaxis monitoring is available. [16]

*Selected prophylactic uterotonic strategies. [16]*

| Clinical context | Preferred approach | Key limitation |
| --- | --- | --- |
| Most facility births | Oxytocin 10 IU IM or IV during the third stage. [16] | Requires quality assurance and refrigerated storage. [16] |
| Vaginal birth with existing IV access | Oxytocin 10 IU diluted and given slowly IV over 1–2 minutes. [16] | Avoid rapid IV injection because of hemodynamic concern. [16] |
| Cold chain unreliable | Heat-stable carbetocin 100 mcg IM or IV; use oral misoprostol 400 or 600 mcg if unavailable. [16] | Carbetocin cost and availability may limit use; misoprostol increases fever, shivering, and diarrhea. [16] |
| No skilled personnel to administer injection | Oral misoprostol 400 or 600 mcg by trained community or lay health workers. [16] | Requires training, supply continuity, counseling, and referral planning. [16] |

## Treat diagnosed PPH as a simultaneous, cause-directed emergency

Avoid serial medication trials while hemorrhage progresses.

Immediately mobilize obstetric, anesthesia, nursing, blood-bank, and surgical support according to local capability. Evaluate the 4Ts in parallel: tone, trauma, tissue, and thrombin. The first-response bundle for vaginal birth includes uterine massage, an oxytocic, IV TXA, isotonic IV fluids, examination of the genital tract and placental completeness, and escalation of care. The pivotal E-MOTIVE trial found that early detection plus bundled treatment reduced severe PPH-related outcomes compared with usual care. [2] WHO recommends initiating all available bundle components within 15 minutes of PPH diagnosis. [16]

IV oxytocin is the recommended first-line uterotonic for treatment, even if oxytocin was used prophylactically. A commonly used initial regimen is 10 IU IV, diluted and administered slowly over 1 to 2 minutes or infused over 5 to 10 minutes; a 10- to 20-IU oxytocin maintenance infusion in crystalloid may be continued for 4 hours, titrated to uterine response and clinical status. [16] If IV oxytocin is unavailable or bleeding does not respond, IV ergometrine, fixed oxytocin-ergometrine, or a prostaglandin drug may be used; sublingual misoprostol 800 mcg is among the cited alternatives, with hyperpyrexia as an important concern. [16]

Administer TXA early, irrespective of whether bleeding is atonic or traumatic. The recommended regimen is 1 g IV at 1 mL/min over 10 minutes, with a second 1-g dose if bleeding continues after 30 minutes or restarts within 24 hours. TXA should not be initiated more than 3 hours after birth because benefit beyond that window has not been demonstrated. Avoid TXA in patients with a clear contraindication to antifibrinolytic therapy, such as a known thromboembolic event during pregnancy. [16]
- Perform sustained therapeutic uterine massage after PPH diagnosis; routine sustained massage is not recommended as prophylaxis in patients who received oxytocin. [16]
- Use isotonic crystalloids rather than colloids for initial volume resuscitation; reassess continuously to avoid fluid overload, especially with preeclampsia or cardiac disease. [16]
- Inspect cervix, vagina, perineum, and operative sites for laceration or hematoma; assess placental completeness and consider retained tissue or uterine inversion when bleeding does not match uterine tone. [16]
- For retained placenta with PPH, provide the PPH bundle and prepare removal. Routine uterotonic treatment of retained placenta without PPH is not recommended. [16]
- Give antibiotic prophylaxis for manual placental removal or intrauterine exploration; suggested options include ampicillin, a first-generation cephalosporin, or single-dose IV amoxicillin 1 g plus clavulanic acid 200 mg, adjusted to allergies and local microbiology. [16]

*First-response PPH bundle and immediate operational purpose. [16]*

| Intervention | Immediate purpose | Critical detail |
| --- | --- | --- |
| Uterine massage | Promote contraction and expel clots inhibiting contraction. [16] | Therapeutic massage begins after PPH is diagnosed. [16] |
| Oxytocic agent | Treat presumed or confirmed uterine atony. [16] | IV oxytocin is first line; do not withhold because prophylactic oxytocin was given. [16] |
| Tranexamic acid | Reduce fibrinolysis in established PPH. [16] | Give 1 g IV over 10 minutes within 3 hours of birth; repeat 1 g once for persistent or recurrent bleeding. [16] |
| Isotonic crystalloid | Support perfusion while definitive hemostasis proceeds. [16] | Use clinical and hemodynamic reassessment to avoid overload. [16] |
| Focused examination | Identify trauma, retained tissue, or alternative bleeding source. [16] | Do not assume atony solely because bleeding is postpartum. [16] |
| Escalation | Prevent delay to mechanical, procedural, operative, and transfusion therapy. [16] | Persistent bleeding after bundle completion requires senior and higher-acuity support. [16] |

## Escalate rapidly when bleeding persists after first-response care

Temporizing maneuvers buy time; they do not replace definitive hemostasis.

For atonic PPH refractory to first-response measures, use bimanual uterine compression and external aortic compression as temporizing maneuvers while definitive treatment, transfer, or operative care is arranged. A nonpneumatic anti-shock garment may also stabilize patients while awaiting blood, surgery, or transfer. [16] These measures require training and may cause significant discomfort; analgesia and clear communication should be provided when feasible. [16]

Uterine balloon tamponade is recommended for atonic PPH after vaginal birth that is unresponsive to standard first-line treatment only when retained tissue and trauma can be reasonably excluded; trained personnel, ongoing maternal monitoring, immediate surgical capability, and blood products must be available. [16] Uterine packing with plain or hemostatic gauze is not recommended because of insufficient evidence and potential to conceal hemorrhage or delay definitive intervention. [16]

When conservative care fails, proceed to definitive intervention without delay. Uterine artery embolization is an option for atony when interventional radiology is timely available; surgical options include compression sutures, vessel ligation, and hysterectomy. WHO advises attempting conservative surgical approaches first when feasible but proceeding to subtotal or total hysterectomy if life-threatening bleeding continues. [16]
- Do not use persistent tamponade or compression as a reason to defer laparotomy, embolization, blood-product resuscitation, or hysterectomy when bleeding or instability continues. [16]
- Use local referral protocols that define stabilization steps, communication with the receiving unit, transport, and documentation of treatments given. [16]
- Cell salvage for PPH is recommended only in rigorous research because evidence for clinically important outcomes remains uncertain. [16]

*Escalation options for refractory PPH. [16]*

| Option | Role | Selection constraint |
| --- | --- | --- |
| Bimanual uterine compression or external aortic compression | Immediate temporizing measure for atony after vaginal birth. [16] | Requires trained personnel and ongoing transition to definitive care. [16] |
| Nonpneumatic anti-shock garment | Temporizing stabilization during transfer or while awaiting definitive treatment. [16] | Does not control the bleeding source. [16] |
| Uterine balloon tamponade | Mechanical treatment for refractory atonic PPH after vaginal birth. [16] | Use only with first-line protocol, trained staff, monitoring, blood access, and immediate surgical recourse. [16] |
| Uterine artery embolization | Potential fertility-preserving definitive option. [16] | Requires timely interventional radiology; prepare surgical alternatives in parallel. [16] |
| Operative hemostasis or hysterectomy | Definitive treatment when conservative measures fail. [16] | Do not delay for repeated unsuccessful conservative attempts. [16] |

## Use blood products according to ongoing hemorrhage, coagulopathy, and local massive-transfusion protocols

Hemoglobin alone is unreliable during acute blood loss.

Transfusion decisions should reflect blood-loss trajectory, hemodynamics, underlying risk, clinical evidence of organ hypoperfusion, serial laboratory assessment, and local protocols. A single hemoglobin or hematocrit may be misleading during acute hemorrhage; serial measurements help monitor treatment but should not delay red-cell transfusion in ongoing unstable bleeding. [16]

WHO advises that massive-transfusion protocols be available where blood-banking capacity exists. In massive PPH, give TXA early; prioritize fibrinogen replacement when coagulopathy is detected or strongly suspected; add plasma for documented factor deficiency or, when testing is delayed during massive blood loss, according to a locally defined empiric approach; and consider platelets for microvascular bleeding with platelet count below 50 × 10^9/L. [16] The guideline describes a commonly used red-cell therapeutic goal of hemoglobin above 70 g/L, while emphasizing that treatment must be individualized to the clinical context. [16]

After hemostasis, monitor recurrent bleeding, vital signs, fluid balance, uterine tone, infection, and anemia. For iron-deficiency anemia after birth, IV iron is preferred over oral iron when oral therapy cannot be used or tolerated, or when severe anemia requires rapid correction and trained personnel can manage anaphylaxis. Severe postpartum anemia is defined in the WHO guidance as hemoglobin 80 g/L or lower. [16]
- Ensure emergency release blood is available under local policy; fully crossmatched red cells are preferred when time permits. [16]
- Consider cryoprecipitate or fibrinogen concentrate where available when fibrinogen is below 2 g/L, targeting at least 2 g/L. [16]
- Provide debriefing, clear discharge precautions, and follow-up for anemia and psychological sequelae after severe PPH. [16]

*Selected blood-product considerations in ongoing PPH. [16]*

| Component or assessment | Guidance |
| --- | --- |
| Red blood cells | Base transfusion on active bleeding and clinical condition, not hemoglobin alone; a commonly cited therapeutic goal is hemoglobin above 70 g/L. [16] |
| Fibrinogen replacement | When fibrinogen is below 2 g/L, give cryoprecipitate where available to target fibrinogen at least 2 g/L. [16] |
| Fresh frozen plasma | Use for documented coagulation-factor deficiency; if laboratory results are delayed in massive hemorrhage, local protocols may use 1 unit FFP per 2 units RBCs. [16] |
| Platelets | Consider for microvascular bleeding when platelet count is below 50 × 10^9/L. [16] |
| Postpartum iron | Use IV iron selectively for likely iron-deficiency anemia when rapid correction is needed or oral iron is unsuitable; monitor for hypersensitivity. [16] |

## Apply newer international thresholds within local U.S. hemorrhage systems

Current evidence supports earlier recognition, but local protocols should define operational escalation.

The 2025 WHO/FIGO/ICM criteria are designed to trigger early first-response treatment and are not a replacement for institutional definitions, massive-transfusion activation criteria, or clinician judgment. They differ from the older ACOG definition centered on at least 1,000 mL cumulative blood loss or hypovolemic signs within 24 hours. [4][16] U.S. services can operationalize both concepts by using quantitative blood loss and physiologic triggers to activate early response while reserving advanced interventions for persistent bleeding, instability, or a confirmed surgical cause.

The key implementation issue is reliability: objective blood-loss measurement must be coupled with ready access to a treatment bundle, hemorrhage cart, anesthesia and blood-bank notification, cause-directed examination, escalation criteria, transfer pathways, and team rehearsal. Formal protocols, simulation training, and audit-feedback systems are specifically recommended to improve PPH readiness and response. [16]
- Track prophylactic uterotonic administration, objective blood-loss documentation, and delivery of the first-response bundle within 15 minutes of PPH diagnosis. [16]
- Expect apparent PPH rates to rise after implementing quantitative measurement; this may reflect improved detection rather than worse care. [16]
- Use institutional pharmacology policies and current U.S. labeling to select second-line uterotonics because the supplied evidence does not provide comprehensive U.S. contraindication or labeling detail for every agent. [16]

*High-value institutional process measures for PPH quality improvement. [16]*

| Measure | Why it matters |
| --- | --- |
| Proportion receiving prophylactic uterotonic within 1 minute after birth | Assesses reliable prevention delivery. [16] |
| Proportion with objectively measured and documented postpartum blood loss | Measures adoption of early-detection infrastructure. [16] |
| Proportion with PPH receiving first-response bundle within 15 minutes | Measures timeliness of coordinated treatment. [16] |
| Severe PPH and PPH-related mortality | Tracks clinical outcomes after implementation. [16] |

## Common questions

### What threshold should trigger treatment for postpartum hemorrhage?

Use objective blood loss of at least 500 mL, or at least 300 mL with pulse above 100/min, shock index above 1, systolic BP below 100 mmHg, or diastolic BP below 60 mmHg, to trigger first-response treatment. Do not delay care for clinically obvious brisk bleeding or instability. [16]

### Should tranexamic acid be given for traumatic as well as atonic PPH?

Yes. TXA is recommended for all established PPH regardless of source, in addition to standard care. Give 1 g IV over 10 minutes as soon as possible and within 3 hours of birth; repeat 1 g once for persistent bleeding after 30 minutes or recurrent bleeding within 24 hours. [16]

### Is visual estimation sufficient for postpartum blood loss?

No. Visual estimation misses many cases: pooled sensitivity was 48% for PPH at 500 mL when compared with gravimetric measurement. Objective collection and measurement, linked to a treatment protocol, should be standard. [24][16]

### When should uterine balloon tamponade be used?

Use it for refractory atonic PPH after vaginal birth after first-line measures fail and after trauma and retained tissue are reasonably excluded. It requires trained staff, monitoring, blood-product access, and immediate surgical backup. [16]

### When should hysterectomy be considered?

Proceed to definitive surgical control when hemorrhage persists despite uterotonics and available conservative interventions. Compression sutures and vessel ligation may be attempted when feasible, but ongoing life-threatening bleeding warrants prompt subtotal or total hysterectomy. [16]

## References
1. Prognostic accuracy of clinical markers of postpartum ... — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01639-3/fulltext
2. Randomized Trial of Early Detection and Treatment ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2303966
3. Prevention and Management of Postpartum Haemorrhage — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178
4. Practice Bulletin No. 183: Postpartum Hemorrhage — journals.lww.com — https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000002351~practice-bulletin-no-183-postpartum-hemorrhage
5. Practice Bulletin No. 183 Summary: Postpartum Hemorrhage — journals.lww.com — https://journals.lww.com/greenjournal/fulltext/2017/10000/practice_bulletin_no__183_summary__postpartum.51.aspx
6. Postpartum haemorrhage in high‐resource settings ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.17551
7. FIGO recommendations on the management of postpartum ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116
8. ACOG Clinical Practice Update: Use of Nonsurgical... — journals.lww.com — https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000006024~acog-clinical-practice-update-use-of-nonsurgical
9. FIGO recommendations on objective measurement of blood ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.70523
10. Management of Postpartum Hemorrhage With... : Obstetrics & Gynecology — journals.lww.com — https://journals.lww.com/greenjournal/abstract/2025/06001/management_of_postpartum_hemorrhage_with.123.aspx
11. Pirlindole - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/pirlindole
12. Misoprostol - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/misoprostol
13. Anti-Inflammatory and Antipyretic Analgesics and Drugs ... — www.sciencedirect.com — https://www.sciencedirect.com/science/chapter/bookseries/pii/S0378608015000331
14. Misoprostol - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/misoprostol
15. Global health agencies issue new recommendations to help end deaths from postpartum haemorrhage — www.who.int — https://www.who.int/news/item/05-10-2025-global-health-agencies-issue-new-recommendations-to-help-end-deaths-from-postpartum-haemorrhage
16. Consolidated guidelines for the prevention, diagnosis ... - IRIS — iris.who.int — https://iris.who.int/server/api/core/bitstreams/88bf11a5-93b6-4d6b-bdaa-856b46c8ed3c/content
17. WHO recommendations for the prevention and treatment of postpartum haemorrhage — www.who.int — https://www.who.int/publications/i/item/9789241548502
18. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage — www.who.int — https://www.who.int/publications/i/item/9789240115637
19. Bleeding after birth training materials — www.who.int — https://www.who.int/tools/bleeding-after-birth
20. WHO guidelines for the management of postpartum ... — iris.who.int — https://iris.who.int/bitstreams/84a5bc9e-e20e-4bb8-9d29-4023a6bb202e/download
21. WHO recommendations for the prevention and treatment of ... — iris.who.int — https://iris.who.int/bitstream/handle/10665/75411/9789241548502_eng.pdf?sequence=
22. Updated WHO Recommendation on Tranexamic Acid for the ... — iris.who.int — https://iris.who.int/bitstreams/239e1345-9f15-42e2-aae0-5b6d2cbeec85/download
23. [Table, Diagnosing postpartum haemorrhage]. - Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK619233/table/ch3.tab26?report=objectonly
24. Tests for diagnosis of postpartum haemorrhage at vaginal birth - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11740288

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.